Author(s): DubischarKastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E
Abstract Share this page
Abstract Japanese encephalitis (JE) is the most common viral encephalitis in Asia. IXIARO is a Vero cell-derived, inactivated JE virus vaccine which has recently been approved in the US, Europe, Canada and Australia (trade name JESPECT). This overview of the safety and tolerability of IXIARO, for 6 months after the first vaccination in 7 Phase III trials, includes: 3558 subjects with at least one IXIARO vaccination, 435 subjects with a JE-VAX (manufactured by BIKEN, distributed by Sanofi Pasteur) vaccination, and 657 with phosphate-buffered saline solution with 0.1\% Al(OH)(3) (PBS+Alum) control vaccination. The percentage of subjects reporting solicited local adverse events (AEs) with IXIARO (54\%) was similar to PBS+Alum vaccination (56\%) as were solicited systemic adverse events (40\% IXIARO; 40\% PBS+Alum vaccination). JE-VAX showed a higher frequency of subjects with solicited local adverse events (61\%) but a slightly lower frequency of subjects with solicited systemic adverse events (36\%). The frequency of subjects with any solicited and unsolicited AE with IXIARO (64\%) was also similar to PBS+Alum vaccination (61\%) and JE-VAX (64\%); as for subjects with serious AEs (1\% IXIARO; 2\% PBS+Alum vaccination, 1\% JE-VAX). No serious allergic reactions were observed in any group. This safety analysis indicates that IXIARO has a favorable safety profile, comparable to PBS+Alum control vaccination and appears to have a better local tolerability profile than JE-VAX. Copyright © 2010 Elsevier Ltd. All rights reserved.
This article was published in Vaccine
and referenced in Journal of Bioterrorism & Biodefense